Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Adriana Walsh

Physician Assistant Athens, OH Physician Assistant

NPI 1245446418 CMS profile 10626168

2111 E State St, Athens, OH 45701

Open in the dashboard

General payments

$14,512

638 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Adriana Walsh of Athens, OH is reported in the CMS Open Payments database as having received $14,512 across 638 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,110 135
2024 General $4,027 132
2023 General $3,029 123
2022 General $1,967 130
2021 General $2,379 118

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Adriana Walsh
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Adriana Walsh were reported at $3,110. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Adriana Walsh Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $2,379 $132 $37–$438 $132
2022 $1,967 $155 $48–$522 $149
2023 $3,029 $167 $52–$557 $160
2024 $4,027 $178 $55–$600 $164
2025 $3,110 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Janssen Biotech, Inc. $3,241 108 payments
  2. AbbVie, Inc. $1,513 89 payments
  3. Novartis Pharmaceuticals Corporation $991 54 payments
  4. Lilly USA, LLC $978 44 payments
  5. Journey Medical Corporation $879 18 payments
  6. Genentech USA, Inc. $764 2 payments
  7. Sun Pharmaceutical Industries Inc. $658 41 payments
  8. E.R. Squibb & Sons, L.L.C. $631 43 payments
  9. Genzyme Corporation $600 25 payments
  10. UCB, Inc. $598 27 payments
  11. Other $3,659 187 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $11,123 622 payments
  2. Consulting Fee $2,313 3 payments
  3. Education $942 11 payments
  4. Travel and Lodging $135 2 payments
Products named General payments · program years 2021–2025
  1. TREMFYA $2,711 59 payments
  2. SKYRIZI $943 59 payments
  3. TALTZ $923 42 payments
  4. DUPIXENT $790 31 payments
  5. Xolair $750 1 payment
  6. SOTYKTU $610 42 payments
  7. SIMPONI ARIA $558 55 payments
  8. STELARA $558 55 payments
  9. SIMPONI $558 55 payments
  10. REMICADE $529 49 payments
  11. Other $7,024 404 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 28 drugs

Part D claims

1,349

Median for Physician Assistant: 241

Drug cost

$1,867,800

Median for Physician Assistant: $4,110

Branded share of claims

21.7%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 118 $440,591
Cosentyx Unoready Pen Secukinumab Brand 43 $362,611
Cosentyx Sensoready (2 Pens) Secukinumab Brand 28 $268,170
Skyrizi Pen Risankizumab-Rzaa Brand 12 $245,694
Tremfya Guselkumab Brand 16 $209,410
Humira(Cf) Pen Adalimumab Brand 16 $170,494
Otezla Apremilast Brand 17 $77,637
Dupixent Syringe Dupilumab Brand 18 $65,756
Clobetasol Propionate Generic 114 $4,536
Betamethasone Dipropionate Generic 100 $3,478

The 10 drugs with the highest cost, of 28 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 56 billing codes

Paid by Medicare

$205,432

Of which drugs: $67,678

Medicare patients

970

Average age 74

Services billed

11,071

545 women, 425 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 71%
Arthritis 48%
Diabetes 26%
Ischemic heart disease 23%
Depression 17%
Chronic kidney disease 16%
COPD 15%
Atrial fibrillation 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Aminolevulinic acid hcl for topical administration, 10% gel, 10 mg J7345 Office 20 5,400 $7,171
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 39 132 $92

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
  • Janssen Biotech, Inc. $1,695
$1,695 16 —
DUPIXENT
  • GENZYME CORPORATION $312
  • SANOFI-AVENTIS U.S. LLC $85
  • Regeneron Healthcare Solutions, Inc. $19
$416 136 —
SKYRIZI
  • AbbVie, Inc. $291
$291 12 —
SOTYKTU
  • E.R. Squibb & Sons, L.L.C. $233
$233 — —
TALTZ
  • Lilly USA, LLC $159
$159 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

638 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record